Redcare Pharmacy’s Next CEO Brings Marketplace Pedigree — But the Share Price Is Still Searching for a Floor

The operational machinery at Redcare Pharmacy keeps humming even as the company’s leadership question dominates investor attention. A new digital dock-scheduling system, dubbed SLOT, has gone live at the company’s Pilsen facility, where it will coordinate roughly ten lorries a day handling inbound and outbound goods.

It is a modest logistical tweak, hardly the stuff of market-moving headlines. But the timing carries symbolic weight: the e-pharmacy operator is fine-tuning its supply chain at the very moment it prepares to hand the chief executive’s office to a manager whose résumé reads more like a Silicon Valley marketplace veteran than a pharmaceutical lifer.

A platform specialist takes the helm

Peter Schmid von Linstow, currently deputy chairman of the supervisory board at Redcare, will step into the CEO role on 1 October, succeeding Olaf Heinrich, who is exiting after three years at the top and will remain available to the company in an advisory capacity. The formal confirmation arrived at an extraordinary general meeting in Sevenum last Tuesday — the same day the stock began its latest leg down, shedding 2.3 percent since.

Schmid von Linstow brings more than two decades of international leadership experience across digital platforms and marketplaces, with stints at Visable (an Alibaba affiliate), the dating service Parship, eBay and AutoScout24. That profile raises an obvious strategic question for Europe’s largest online pharmacy: does his arrival signal a pivot toward a more open, third-party marketplace model — a departure from the traditional pharmacy logistics in which Redcare is rooted?

The company has not indicated any such repositioning, and the market is clearly reserving judgment.

Solid numbers, stubborn chart

Strip away the personnel drama and the underlying business is performing respectably. First-half 2026 revenue climbed 19 percent to EUR 1.7 billion, with the German prescription (Rx) business surging 58 percent. Active customer numbers rose 9 percent to 14.7 million.

Should investors sell immediately? Or is it worth buying Redcare Pharmacy?

That momentum prompted management to lift full-year guidance roughly two weeks ago, targeting revenue growth of 15 to 17 percent and an EBITDA margin between 2.5 and 3 percent. Yet the share has given back 4.4 percent since that upgrade — evidence that the market is not yet translating operational strength into a sustained re-rating.

The stock did manage a 4.7 percent bounce at last week’s close, landing at EUR 59.65. Still, that leaves the equity roughly 34 percent below its twelve-month high of EUR 90.05, set in early October, and nearly 8 percent beneath its 50-day moving average of EUR 64.66. Year to date, the shares are down 9.3 percent.

A dual-edged signal for investors

The combination of a marketplace-savvy incoming CEO and robust operating metrics cuts both ways. On one hand, Schmid von Linstow’s background in scaling digital ecosystems could inject fresh thinking into Redcare’s growth playbook. On the other, he steps into a heavily regulated pharmaceutical distribution environment where a steep learning curve is all but guaranteed — a risk that a manager without pharmacy-specific credentials cannot simply wave away.

The Pilsen logistics upgrade, small as it is, offers a counterpoint to the leadership uncertainty. It signals that day-to-day operations are proceeding on autopilot, independent of who formally occupies the corner office after October. For investors fretting that the transition could derail the growth narrative, that is a modest but tangible reassurance.

Until the new chief lays out his strategic priorities, the market will keep parsing every operational dispatch for clues about continuity. With annualized volatility running at 51 percent, this remains a stock that demands a steady hand — and a clear-eyed view of the gap between what the business is delivering and what the share price is reflecting.